University of California, Los Angeles - UCLA
Welcome,         Profile    Billing    Logout  
 17 Trials 
34 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Schiller, Gary J
NCT03926624: Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Recruiting
3
450
US
DFP-10917, Cytarabine, Azacitidine, Decitabine, Mitoxantrone, Etoposide, Fludarabine, Idarubicin, Venetoclax, Cladribine
Delta-Fly Pharma, Inc.
Leukemia, Myeloid, Acute
12/22
12/22
MANIFEST-2, NCT04603495 / 2020-001989-10: Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF)

Hourglass Jul 2024 - Dec 2024 : Regulatory submission in EU for 1L myelofibrosis
Jan 2024 - Dec 2024: Approval for myelofibrosis
Jan 2024 - Mar 2024: From MANIFEST-2 trial in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis
Feb 2024 - Feb 2024: Completion of P2b trial for JIA
Feb 2024 - Feb 2024: Exclusivity expiry in US
Active, not recruiting
3
430
Europe, Canada, US, RoW
Pelabresib, Ruxolitinib, Placebo
Constellation Pharmaceuticals
Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
08/23
12/27
NCT06401356: An Extension Study for Patients Previously Enrolled in Studies with Pelabresib

Recruiting
3
50
Europe, US
Pelabresib, CPI-0610
Constellation Pharmaceuticals
Hematologic Malignancy, Solid Tumor, Advanced Malignancies
06/29
06/29
NCT04260698: Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies

Active, not recruiting
3
36
US
omidubicel, NiCord
Gamida Cell ltd
Hematological Malignancies
05/25
05/25
SENTRY, NCT04562389: Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis

Checkmark Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
Hourglass Dec 2022 - Dec 2022 : Data from trial in combination with ruxolitinib myelofibrosis
Checkmark Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
More
Recruiting
3
350
Europe, Canada, US, RoW
Selinexor, KPT-330, Placebo, Ruxolitinib
Karyopharm Therapeutics Inc
Myelofibrosis
09/25
03/28
BP1001-201-AML, NCT02781883: Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML

Recruiting
2a
108
US
BP1001 in combination with Ventoclax plus decitabine, Liposomal Grb-2, L-Grb-2, BP1001 plus decitabine
Bio-Path Holdings, Inc.
Acute Myeloid Leukemia (AML)
12/24
12/24
NCT04231851: CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia

Active, not recruiting
2
30
US
Glasdegib, DAURISMO™, CPX-351, Daunorubicin and cytarabine, VYXEOS®
University of California, Irvine, Jazz Pharmaceuticals, Pfizer
Acute Myelogenous Leukemia (AML) Due to Therapy, Acute Myeloid Leukemia With Myelodysplasia-Related Changes
06/25
06/27
SELECT-AML-1, NCT04905407 / 2021-003910-38: Tamibarotene Plus Venetoclax/Azacitidine in Participants with Newly Diagnosed AML

Active, not recruiting
2
95
Europe, US
Tamibarotene, Venetoclax, Venclexta, Azacitidine, Vidaza
Syros Pharmaceuticals, Syros Pharmaceuticals, Inc.
Acute Myeloid Leukemia
04/28
04/28
NCT04562870 / 2020-003809-60: A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants with Previously Treated Myelofibrosis

Hourglass Jul 2023 - Dec 2023 : Top-line data from XPORT-MF-035 trial for myelofibrosis
Checkmark First patient dosed as a monotherapy in patients with 2L myelofibrosis
Dec 2021 - Dec 2021: First patient dosed as a monotherapy in patients with 2L myelofibrosis
Active, not recruiting
2
112
Europe, US, RoW
Selinexor, Physician's Choice Treatment
Karyopharm Therapeutics Inc
Myelofibrosis
01/25
01/25
ASC2ESCALATE, NCT05384587: Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia

Active, not recruiting
2
196
US
asciminib, ABL001
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia - Chronic Phase
09/25
10/27
GRASP, NCT05353647: A Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell Disease (, BMT CTN 2001)

Active, not recruiting
2
25
US
Autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a
David Williams, National Heart, Lung, and Blood Institute (NHLBI), California Institute for Regenerative Medicine (CIRM), bluebird bio, Blood and Marrow Transplant Clinical Trials Network
Sickle Cell Disease
05/26
05/26
KCP-8602-801, NCT02649790 / 2021-003810-38: Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

Checkmark From trial for myelodysplastic syndrome at ASH 2019
Dec 2019 - Dec 2019: From trial for myelodysplastic syndrome at ASH 2019
Active, not recruiting
1/2
277
Europe, Canada, US, RoW
KPT-8602, Eltanexor, ASTX727, Dexamethasone
Karyopharm Therapeutics Inc, Karyopharm Therapeutics Inc.
Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Higher-Risk Myelodysplastic Syndrome (HR-MDS), Acute Myeloid Leukemia (AML), Newly Diagnosed Intermediate/High-Risk MDS
08/24
12/24
CADENZA, NCT03386513 / 2018-003210-40: Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

Hourglass Jan 2024 - Dec 2024 : Top-line data from cohort 6 for 1L BPCDN
Active, not recruiting
1/2
179
Europe, US
IMGN632
AbbVie
Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Neoplasm
09/23
12/26
STOMP, NCT02343042: Selinexor and Backbone Treatments of Multiple Myeloma Patients

Hourglass Feb 2024 - Dec 2024 : Results from STOMP trial for RRMM and NDMM
Checkmark From STOMP trial in combination with Pomalyst & low dose dexamethasone for r/r multiple myeloma
Jun 2021 - Jun 2021: From STOMP trial in combination with Pomalyst & low dose dexamethasone for r/r multiple myeloma
Checkmark Data from STOMP trial in combination with lenalidomide and dexamethasone for multiple myeloma at ASH 2020
Dec 2020 - Dec 2020: Data from STOMP trial in combination with lenalidomide and dexamethasone for multiple myeloma at ASH 2020
More
Recruiting
1/2
300
Canada, US
Selinexor, KPT-330, XPOVIO®, Dexamethasone, Decadron®, Lenalidomide, Revlimid®, Pomalidomide, Pomalyst®, Bortezomib, Velcade®, Daratumumab, Darzalex®, Carfilzomib, Kyprolis®, Ixazomib, Ninlaro®, Elotuzumab, Empliciti®, Clarithromycin, Biaxin, Belantamab Mafodotin, BLENREP, Mezigdomide, BMS-986348, CC-92480
Karyopharm Therapeutics Inc, Bristol-Myers Squibb
Multiple Myeloma
04/27
04/27
OPAL, NCT04329728: The Study: AVM0703 for Treatment of Lymphoid Malignancies

Recruiting
1/2
144
US
AVM0703, Supra-Pharmacologic Dexamethasone Phosphate
AVM Biotechnology Inc, Medpace, Inc.
Lymphoid Malignancies
04/25
06/25
NCT04536792: A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease

Completed
1
122
Europe, US
AG-946, AG-946 Matched Placebo
Agios Pharmaceuticals, Inc.
Healthy Volunteers, Anemia, Sickle Cell
12/23
12/23
BP1002-102-AML, NCT05190471: A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)

Recruiting
1
48
US
BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide, Liposomal Bcl-2; L-Bcl-2, Decitabine (in combination with BP1002), Decitabine
Bio-Path Holdings, Inc.
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
03/24
09/24
SENTI-202-101, NCT06325748: SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

Recruiting
1
21
US, RoW
SENTI-202, Fludarabine, Cytarabine (ara-C)
Senti Biosciences
AML/MDS, CD33 Expressing Hematological Malignancies, FLT3 Expressing Hematological Malignancies
09/25
08/40
NCT06226571: A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias

Recruiting
1
76
US
SNDX-5613, Chemotherapy Regimen, HiDAC
Syndax Pharmaceuticals
Acute Myeloid Leukemias
02/27
02/27
CLN-049-001, NCT05143996: CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Recruiting
1
60
US
CLN-049
Cullinan Oncology Inc.
Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
08/25
11/25
Habtemariam, Bruck
NCT03926624: Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Recruiting
3
450
US
DFP-10917, Cytarabine, Azacitidine, Decitabine, Mitoxantrone, Etoposide, Fludarabine, Idarubicin, Venetoclax, Cladribine
Delta-Fly Pharma, Inc.
Leukemia, Myeloid, Acute
12/22
12/22
MANIFEST-2, NCT04603495 / 2020-001989-10: Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF)

Hourglass Jul 2024 - Dec 2024 : Regulatory submission in EU for 1L myelofibrosis
Jan 2024 - Dec 2024: Approval for myelofibrosis
Jan 2024 - Mar 2024: From MANIFEST-2 trial in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis
Feb 2024 - Feb 2024: Completion of P2b trial for JIA
Feb 2024 - Feb 2024: Exclusivity expiry in US
Active, not recruiting
3
430
Europe, Canada, US, RoW
Pelabresib, Ruxolitinib, Placebo
Constellation Pharmaceuticals
Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
08/23
12/27
Precision-T (PhIII component), NCT05316701: Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Active, not recruiting
3
174
US
Orca-T, Standard-of-Care, SOC
Orca Biosystems, Inc.
Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia, Undifferentiated Leukemia, Myelodysplastic Syndrome, Acute Leukemia, Therapy-Related Myelodysplastic Syndrome
04/25
04/27
E-CELERATE, NCT05181540: A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation

Terminated
3
130
US
AB-205, E-CEL cells, Placebo
Angiocrine Bioscience, California Institute for Regenerative Medicine (CIRM)
Hodgkin Lymphoma, Non Hodgkin Lymphoma
12/23
01/25
BP1001-201-AML, NCT02781883: Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML

Recruiting
2a
108
US
BP1001 in combination with Ventoclax plus decitabine, Liposomal Grb-2, L-Grb-2, BP1001 plus decitabine
Bio-Path Holdings, Inc.
Acute Myeloid Leukemia (AML)
12/24
12/24
KB-LANRA- 1001, NCT05028751 / 2022-001279-15: A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)

Terminated
1/2
24
Europe, US
Lanraplenib, LANRA, Gilteritinib, XOSPATA®
Kronos Bio, Kronos Bio, Inc.
Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
04/24
04/24
KOMET-001, NCT04067336 / 2019-001545-41: First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

Recruiting
1/2
199
Europe, Canada, US
Ziftomenib
Kura Oncology, Inc., Kura Oncology, Inc.
Advanced Malignant Neoplasm, Acute Myeloid Leukemia, Mixed Lineage Leukemia, Mixed Lineage Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Mixed Phenotype Acute Leukemia
09/24
09/25
OPAL, NCT04329728: The Study: AVM0703 for Treatment of Lymphoid Malignancies

Recruiting
1/2
144
US
AVM0703, Supra-Pharmacologic Dexamethasone Phosphate
AVM Biotechnology Inc, Medpace, Inc.
Lymphoid Malignancies
04/25
06/25
IO-202-CL-001, NCT04372433: IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML

Active, not recruiting
1
106
US
IO-202, IO-202 and Azacitidine, IO-202 and AZA, IO-202 and Azacitidine + Venetoclax, IO-202 and AZA + Ven
Immune-Onc Therapeutics, California Institute for Regenerative Medicine (CIRM)
AML With Monocytic Differentiation, CMML
01/26
01/27
SL03-OHD-104, NCT05275439: Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects with MDS or AML

Active, not recruiting
1
160
Europe, Canada, US
SL-172154, Azacitidine, Venetoclax
Shattuck Labs, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndromes
11/24
11/24
SENTI-202-101, NCT06325748: SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

Recruiting
1
21
US, RoW
SENTI-202, Fludarabine, Cytarabine (ara-C)
Senti Biosciences
AML/MDS, CD33 Expressing Hematological Malignancies, FLT3 Expressing Hematological Malignancies
09/25
08/40
CLN-049-001, NCT05143996: CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Recruiting
1
60
US
CLN-049
Cullinan Oncology Inc.
Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
08/25
11/25
KOMET-007, NCT05735184: A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination with Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients with AML

Recruiting
1
212
US
Ziftomenib, Venetoclax, Azacitidine, Daunorubicin, Cytarabine
Kura Oncology, Inc.
Acute Myeloid Leukemia, Mixed Lineage Acute Leukemia, Mixed Lineage Leukemia Gene Mutation, Mixed Phenotype Acute Leukemia, Refractory AML, AML with Mutated NPM1, Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, in Relapse, NPM1 Mutation, KMT2Ar, Myeloid Sarcoma
05/26
05/27
NCT06001788: Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Recruiting
1
171
US
Ziftomenib, KO-539, Fludarabine, Idarubicin, Cytarabine, Gilteritinib, Xospata, Granulocyte colony-stimulating factor
Kura Oncology, Inc.
AML, AML With Mutated NPM1, Hematologic Malignancy, KMT2Ar, NPM1 Mutation, MLL Rearrangement, Leukemia, Acute Myeloid Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Acute Leukemia, Neoplasms by Histologic Type
08/26
08/27

Download Options